 | « Back to article | Print this article |
In a bid to foray into the German critical care market, Claris Lifesciences, the Ahmedabad-based critical care and hospital disposable product company, has tied up with Plasma Select, one of the top hospital supply companies in Germany.
The marketing alliance with Plasma Select would initially involve sales of two complex hospital products -- Lipid Emulsion and Propofol injection. The German market for these two products is pegged at $200 million.
Claris CMD Sushil Handa told Business Standard that the company has already initiated first supply of its complex Lipid Emulsion to Delta Select, the critical care supply arm and subsidiary of Plasma Select, through this marketing arrangement.
"The company would introduce four to five products soon in the German market and another 20 products by the next one or two years, he said.
"Germany is the biggest pharmaceutical market in Europe, and the third largest in the world after USA and Japan. Claris has crossed one big milestone in the successful implementation of its regulated markets strategy, gaining access to the highly stringent European Union markets. With this, we have joined the ranks of very few companies in the world outside of Europe and the US, to supply such complex products to the EU," he added.
In the global critical care market, Claris is currently focusing on the regulated markets including Europe, US, Australia and New-Zealand. The European and US market together are estimated to be around $120 billion.
Do you want to discuss stock tips? Do you know a hot one? Join the Stock Market Investments Discussion Group
